drugset / Trial / NCT00325195

Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout

NCT00325195

Phase 3 Completed 225 enrolled Savient Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

These are two replicate studies to evaluate the safety and efficacy of PEG (polyethylene glycol)-uricase in controlling the uric acid level in symptomatic gout patients with high uric acid levels who are unable to take standard gout therapies, or for whom those therapies have been unsuccessful in controlling their uric acid level.

Timeline

Start
2006-05
Primary completion
2007-10
Completion
2007-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegloticase Protein / enzyme biologic 8 mg Intravenous

Indications